Saturday 17 October 2026
Export STRO’s income statement to Excel — free account
Sutro Biopharma, Inc.
STRO Healthcare Biotechnology
Sutro Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $102.5 million, up 65.2% from fiscal 2024. In the quarter to June 2026, revenue fell 84.6%, EPS fell 66.4% and free cash flow grew 14.6%, each against the same quarter a year earlier.
10.94
0.52
−4.54%
Follow STRO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 266.76% | 331.40% | 435.02% | (1,810.01%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
3 | 5 | 3 | 1 | |
| (79.08%) | (54.53%) | (68.12%) | (65.54%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(137.78%) | (96.29%) | (221.06%) | (175.43%) | |
Average Days of Receivables |
46.30 | 45.75 | 14.16 | 13.55 | |
Free Cash Flow per Share |
(8.79) | (11.63) | (21.06) | (26.52) | |
Free Cash Flow |
(145.62) | (152.14) | (178.93) | (225.11) | |
Capital Expenditures |
(0.45) | (0.53) | (1.69) | (2.58) | |
| Other line items | |||||
Cash ROIC |
(238.61%) | (112.14%) | (1,993.38%) | (280.25%) | |
Accounts Receivable Turnover |
6.63 | 7.65 | 16.28 | 19.98 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.01 | 0.00 | |
Research and Development Expense of Revenue |
316.71% | 151.97% | 162.38% | 190.08% | |
Selling, General and Administrative Expense of Revenue |
71.81% | 35.47% | 40.02% | 39.18% | |
Share Based Compensation of Revenue |
14.83% | 10.07% | 13.67% | 17.29% | |
Operating CF/Net income |
0.80 | 0.99 | 0.93 | 1.03 | |
Depreciation/Fixed assets |
0.46 | 0.42 | 0.37 | 0.23 | |
Capex/Depreciation |
(0.11) | (0.14) | (0.44) | (0.83) | |
Revenue per Share |
2.76 | 7.61 | 12.06 | 12.45 | |
Operating CF per Share |
(8.76) | (11.59) | (20.86) | (26.22) | |
Capex per Share |
(0.03) | (0.04) | (0.20) | (0.30) | |
Capex to Sales |
0.01 | 0.01 | 0.02 | 0.02 |
Columns are period end dates